Emerging Technologies in Liquid Biopsy of Cancers

Dear Colleagues,

Liquid biopsy is revolutionizing the diagnosis and monitoring of cancer by enabling the non-invasive detection of tumor-derived biomarkers (e.g., ctDNA, CTCs, exosomes) in blood or other biofluids. This Special Issue explores cutting-edge technological advances in the field, with an emphasis on novel methodologies such as high-sensitivity detection platforms (single-cell analysis, microfluidics, CRISPR-based assays), multi-omics integration (fragmentomics, epigenomics, proteomics), and AI-driven bioinformatics pipelines; emerging biomarkers, with the discovery and validation of novel signatures (cfDNA fragmentation patterns, methylation profiles, metabolite panels) for early cancer detection, the monitoring of minimal residual disease, and the prediction of therapy resistance; and clinical translation, with developments addressing challenges such as low-abundance target isolation, the standardization of pre-analytical protocols, and longitudinal monitoring to accelerate clinical adoption. We welcome original research, reviews, and perspectives on in silico biomarker discovery, point-of-care devices, nanotechnology applications, and multi-modal liquid biopsy frameworks. Submissions should highlight technological novelty, analytical/clinical validation, and translational potential across solid and hematologic malignancies. This Special Issue invites innovators, clinical researchers, and biotech stakeholders to contribute to this Special Issue and shape the next generation of precision oncology tools.

Dr. Lingdi Yin
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.